Adis Summary of Research: Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents

被引：0
|
作者：
Paik, Julia [1 ]
Al-Salama, Zaina T. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2023年 / 39卷 / 09期
关键词：
D O I：
10.1007/s40267-023-01010-3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Coronavirus disease 2019 (COVID-19) has a high mortality rate among the elderly, particularly among frailer and older individuals living in long-term care facilities (LTCFs). In Spain, a large number of patients in this priority group had received the COVID-19 vaccine, including the mRNA vaccine BNT162B2, by April 2021. This Adis Summary of Research summarizes the effects of the BNT162B2 mRNA vaccine among residents in an LTCF in Spain, based on an observational study. Vaccination in elderly LTCF residents was not linked with an increased safety risk, with no apparent contraindications even in more frail individuals.
引用
收藏
页码：317 / 318
页数：2
相关论文
共 50 条
  • [41] The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation
    Watanabe, Marika
    Yakushijin, Kimikazu
    Funakoshi, Yohei
    Ohji, Goh
    Hojo, Wataru
    Sakai, Hironori
    Saeki, Miki
    Hirakawa, Yuri
    Matsumoto, Sakuya
    Sakai, Rina
    Nagao, Shigeki
    Kitao, Akihito
    Miyata, Yoshiharu
    Koyama, Taiji
    Saito, Yasuyuki
    Kawamoto, Shinichiro
    Ito, Mitsuhiro
    Murayama, Tohru
    Matsuoka, Hiroshi
    Minami, Hironobu
    VACCINES, 2022, 10 (02)
  • [42] Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study
    Itzhaki Ben Zadok, Osnat
    Shaul, Aviv A.
    Ben-Avraham, Binyamin
    Yaari, Vicky
    Ben Zvi, Haim
    Shostak, Yael
    Pertzov, Barak
    Eliakim-Raz, Noa
    Abed, Galia
    Abuhazira, Miriam
    Barac, Yaron D.
    Mats, Israel
    Kramer, Mordechai R.
    Aravot, Dan
    Kornowski, Ran
    Ben-Gal, Tuvia
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (09) : 1555 - 1559
  • [43] Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients
    Ligumsky, Hagai
    Safadi, Esraa
    Etan, Tal
    Vaknin, Noam
    Waller, Manuel
    Croll, Assaf
    Nikolaevski-Berlin, Alla
    Greenberg, Inbal
    Halperin, Tami
    Wasserman, Asaf
    Galazan, Lior
    Arber, Nadir
    Wolf, Ido
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (02): : 203 - 209
  • [44] Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy
    Milano, Eugenio
    Ricciardi, Aurelia
    Casciaro, Raffaella
    Pallara, Elisabetta
    De Vita, Elda
    Bavaro, Davide F.
    Larocca, Angela Maria Vittoria
    Stefanizzi, Pasquale
    Tafuri, Silvio
    Saracino, Annalisa
    JOURNAL OF MEDICAL VIROLOGY, 2022, 94 (05) : 2230 - 2236
  • [45] Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
    Naruse, Hiroyuki
    Ito, Hiroyasu
    Izawa, Hideo
    Sarai, Masayoshi
    Ishii, Junnichi
    Sakaguchi, Eirin
    Murakami, Reiko
    Ando, Tatsuya
    Fujigaki, Hidetsugu
    Saito, Kuniaki
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
  • [46] Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations
    Campagna, Roberta
    Mazzuti, Laura
    Guerrizio, Giuliana
    Nonne, Chiara
    Migliara, Giuseppe
    De Vito, Corrado
    Mezzaroma, Ivano
    Chiaretti, Sabina
    Fimiani, Caterina
    Pistolesi, Valentina
    Morabito, Santo
    Turriziani, Ombretta
    VACCINE: X, 2022, 12
  • [47] Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in patients with multiple myeloma three and six months after vaccination
    Silzle, T.
    Fischer, S.
    Driessen, C.
    Nigg, S.
    Demmer, R.
    Albrich, W. C.
    Kahlert, C. R.
    SWISS MEDICAL WEEKLY, 2021, 151 : 24 - 25
  • [48] Correction to: Immunogenicity and safety of the mRNA-based BNT162b2 vaccine in systemic autoimmune rheumatic diseases patients
    Yael Pri-Paz Basson
    Oshrat E. Tayer-Shifman
    Rawand Naser
    Shelly Tartakover Matalon
    Oded Kimhi
    Raz Gepstein
    Tamar Halperin
    Tomer Ziv-Baran
    Amit Ziv
    Roma Parikh
    Shaye Kivity
    Yair Levy
    Clinical Rheumatology, 2022, 41 : 3925 - 3925
  • [49] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients
    Shem-Tov, Noga
    Yerushalmi, Ronit
    Danylesko, Ivetta
    Litachevsky, Vladislav
    Levy, Itzchak
    Olmer, Liraz
    Lusitg, Yaniv
    Avigdor, Abraham
    Nagler, Arnon
    Shimoni, Avichai
    Rahav, Galia
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) : 884 - 891
  • [50] Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
    Levy, Itzchak
    Wieder-Finesod, Anat
    Litchevsky, Vladyslav
    Biber, Asaf
    Indenbaum, Victoria
    Olmer, Liraz
    Huppert, Amit
    Mor, Orna
    Goldstein, May
    Levin, Einav Gal
    Hod, Tammy
    Cohen, Carmit
    Lustig, Yaniv
    Rahav, Galia
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (12) : 1851 - 1855
12345